Dyne Therapeutics officer proposes $43.8K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Dyne Therapeutics, Inc. officer Doug Kerr reported a proposed sale of 2,604 common shares, with an approximate sale date of November 13, 2026 and an aggregate market value of $43,810. The notice lists prior sales of 3,745 shares on September 4, 2026, for gross proceeds of $91,187, and 1,290 shares on September 8, 2026, for gross proceeds of $24,360. Azad Daswani signed as Stifel’s duly authorized representative and attorney-in-fact for Doug Kerr.
Key Figures
Key Terms
Restricted Stock Units financial
Equity Compensation financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What proposed sale did DYN officer Doug Kerr report?
What did DYN officer Doug Kerr acquire?
AI-generated analysis. How Rhea-AI works. Not financial advice.